Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TWIST
2008-000928-71Phase 2Active
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Jul 2008
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-clear cell renal cell carcinoma (nccRCC) comparing Temsirolimus with Temsirolimus + low-dose interferon alfa-2a (2 arms). Primary endpoint: Progression-free survival. Started Jul 2008; status: active.
02
Drugs
temsirolimusinterferon alfa-2a
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on 2008-000928-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000928-71.